The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

OTEZLA IMPROVES NAIL PSORIASIS1*

Sustained improvement in nail psoriasis up to 1 year in ESTEEM 11,a

 

aESTEEM 1 study. Data as observed; includes patients initially randomized to OTEZLA 30 mg BID or placebo at week 0 who were PASI-75 responders at week 32 and continued to receive OTEZLA through week 52.

  • In ESTEEM 1, treatment with OTEZLA resulted in significantly greater improvement in Nail Psoriasis Severity Index (NAPSI) score vs placebo at week 16 (mean percent change from baseline: 22.5% vs 6.5%; P < 0.0001)1†

See the OTEZLA difference

Real psoriasis patients, real pictures.

Actual patient with nail psoriasis before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Baseline

Actual patient with nail psoriasis after 16 weeks of treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Week 16

Individual results may vary.

Actual patient with nail psoriasis after 32 weeks of treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Week 32

Individual results may vary.

*In patients with nail psoriasis at baseline (NAPSI score >1; 558/844, 66.1%).

Full analysis set, LOCF.

Actual real-world OTEZLA patient. Property of Amgen Inc.

Reference:

  1. Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Amer Acad Dermatol. 2015;74(1):134-142.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.